The role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment

Abstract

Chronic venous diseases of the lower extremities, including varicose veins, are one of the most common pathologies in modern society, affecting up to 73% of women and up to 56% of men. Despite significant advances in surgical treatment, the role of conservative therapy in the treatment of this disease does not diminish. The main group of drugs used in the conservative treatment of venous pathology are the so-called phlebotropic drugs, which are a fairly diverse group of medications of both natural and synthetic origin. One of the leading places among phlebotropic drugs is occupied by micronized purified flavonoid fraction, which is a venoactive drug consisting of diosmin 900 mg and flavonoids, in terms of hesperidin 100 mg. The effectiveness of micronized purified flavonoid fraction in relation to venous symptoms, including pain, heaviness, edema, trophic disorders and others has been demonstrated in many studies. When using MPFF, venous trophic ulcers healed faster and more frequently than in the control group without the drug. The drug was effective in patients who received invasive treatment for varicose veins, both sclerotherapy and open and endovascular interventions. The drug also proved itself in patients with various comorbid disorders, such as phlebogonarthrosis. There is a significant amount of data demonstrating the effectiveness of MPFF in pelvic varicose veins. Currently, in addition to the original drug, there are 4 generics on the market, to which, according to the current point of view, the effects proven in the study of the original drug cannot be transferred. However, the drug Detravenol in a comparative study demonstrated the same efficacy and safety profile as the original drug. This gives our patients the opportunity to choose between the original and the reproduced drug.